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Abstract 
 The replication of DNA is vital to the survival of any organism.  The ability to replicate 
DNA, however, is compromised by the continual onslaught of DNA damaging agents, which 
include UV light, oxidative stress, and a variety of environmental pollutants. DNA damage stalls 
the replication of the genome by the normal replicative polymerases.  Thus, in order for cell 
survival, this damage must either be repaired or overcome by translesion synthesis.  The X- and 
Y- families of DNA polymerases have been implicated in these cell survival pathways.  These 
families of DNA polymerases have roles in both the bypass of DNA lesions as well as filling 
gaps in DNA synthesis.  Despite the significance of their function, many aspects of the 
mechanism by which these DNA polymerases overcome DNA damage are largely unknown.  
Thus, there is an obvious need to investigate the structure, function, and the mechanism of 
translesion synthesis of specific X- and Y- family polymerases.  
 The first part of this thesis will investigate how Y-family DNA polymerases are able to 
bypass a specific lesion, known as -(deoxyguanosin-8-yl)-1-aminopyrene (dGAP), in the DNA.   
The first chapter will report on the determination of the kinetic mechanism of translesion 
synthesis opposite this lesion by a model Y-family DNA polymerase, Sulfolobus sulfataricus 
DNA polymerase IV (Dpo4).  Pre-steady-state kinetic methods were employed to investigate the 
incorporation of individual nucleotides upstream, downstream, and opposite the site of the dGAP 
lesion. Our results showed that Dpo4 was able to bypass this bulky lesion, but was inefficient in 
its replication opposite the lesion and immediately downstream of the lesion.  The inefficient 
bypass also corresponded to a decrease in enzyme fidelity at these two sites.  Moreover, our 
studies indicated that the kinetics of nucleotide incorporation at these sites was biphasic, in 
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which a small, fast phase was followed by a larger, slow phase.  The results from the various 
kinetic studies performed to investigate Dpo4’s bypass of the dGAP lesion are reported in the first 
chapter.  These results have also been previously published in the Journal of Biological 
Chemistry [1].  
The second part of the thesis describes the efficiency and mutagenic characterization of 
the bypass of the dGAP lesion by the model Y-family DNA polymerase Dpo4, as well as two 
human Y-family DNA Polymerases, human DNA polymerases kappa and eta. To determine the 
mutagenic profile for each of these enzymes, a novel assay, known as Short Oligonucleotide 
Sequencing Assay (SOSA), was utilized.  First, running start assays established that all three Y-
family polymerases were capable of bypassing the dGAP lesion.  It was shown that DNA 
polymerase eta did so with the most efficiency.  However, when comparing the mutagenic 
profiles of these three polymerases, it was shown that Dpo4 had the greatest fidelity. When 
comparing the human Y-family DNA polymerases, human DNA polymerase kappa had an 
overall greater fidelity than DNA polymerase eta.  These results are discussed in Chapter 2.   
In the third part of the thesis, we determined if nucleoside analogs, a class of antiviral 
drug, are potential substrates for human X- and Y- family polymerases. Human DNA 
polymerase λ, which putatively functions in base excision repair, and human DNA polymerase η, 
which functions in translesion synthesis, were chosen as representative members of the X- and 
Y- family enzymes, respectively. Several major drugs, including entecavir, zidovudine, 
tenofovir, adefovir, emtricitabine, and ribovarin, were chosen, since they are currently being 
used in hepatitis B and HIV-1 clinical virology to treat the  millions of people infected 
worldwide. Single nucleotide incorporation assays were used to measure the substrate specificity 
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for the natural nucleotides and their respective nucleotide analog. By comparing these substrate 
specificities, the probability of the nucleotide analog being incorporated into DNA by DNA 
polymerases λ and η could be determined. Interestingly, the order of substrate preference was 
different for Polλ (emtricitabine< tenofovir< adefovir<zidovudine< entecavir) and Polη 
(tenofovir<zidovudine<emtricitabine<adefovir<entecavir). Kinetic results suggest that X- and Y-
family DNA polymerases may incorporate these drugs in vivo.    
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Chapter 1: Bypass Mechanism of a Lesion Formed from 1-
itropyrene by a Y-family DA Polymerase 
Background and Introduction 
As previously stated, replication of genomic material is essential to the growth and 
reproduction of any organism.  The process of DNA replication is complicated and compromised 
by DNA damaging agents, which include UV light, oxidative stress, and a variety of 
environmental pollutants [2, 3].  Environmental pollutants have been shown to affect human 
health at the molecular level.  For example, they can modify genomic DNA by introducing 
lesions to nucleotides [3].  These lesions will stall the principal replicative DNA polymerases 
and thus inhibit the replication of the cellular genome [4, 5].  The cell has two basic ways to 
overcome damaged DNA and the stalling of replication: i) Recognition of the lesion and removal 
by the cellular DNA repair machinery or ii) Displacement of the principal replicative DNA 
polymerase and continued polymerization by lesion bypass DNA polymerases, which transverse 
the unrepaired lesions.  The Y-family DNA polymerases are principally responsible for 
translesion synthesis due to their relatively flexible and solvent accessible active sites, though,  
the Y-family DNA polymerases synthesize DNA with a low fidelity and processivity [6].  The 
Y-family of DNA polymerases are found in the three domains of life - Archea, Bacteria, and 
Eukaryota.  In humans, four Y-family DNA polymerases have been identified (DNA 
polymerases Rev1, η, ι, and  κ).  Sulfolobus solfataricus DNA polymerase IV (Dpo4), a model 
Y-family DNA polymerase was utilized for the following study.  Dpo4 was chosen for its high 
thermostability, relative ease of expression in E. coli and subsequent purification, as well as 
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because it has been extensively studied in vitro [7].  In addition, Dpo4 has been shown to  be 
capable of bypassing a variety of DNA lesions including apurinic/apyrimidinic (abasic) sites [8], 
cis-syn thymine-thymine dimers [9], cisplatin-induced 1,2-intrastrand cross links with adjacent 
deoxyguanosines [10], and benzo[a]pyrene diol epoxides on deoxyguanosines (BPDE-dG) [11].  
 Dpo4 will be utilized to study the bypass of a 1-nitropyrene (1-NP)-induced lesion 
because there have been no mechanistic studies of this process in vitro.  1-NP, an abundant 
polycyclic aromatic hydrocarbon (PAH) compound, is produced due to incomplete diesel and 
gasoline combustion [2, 3].   Metabolism of 1-NP takes place through two known pathways:  
nitroreduction (Scheme 1.1) and C-hydroxylation.   If 1-NP is oxidized into non-DNA-reactive 
metabolites by P40 enzymes while in the gastrointestinal tract, respiratory system or skin, the 
organism can excrete the metabolites through a detoxification process [12, 13].  However, if the 
1-NP proceeds through nitro reduction, DNA-reactive metabolites will be formed (Scheme 1.1) 
[12].  As seen in Scheme 1.1, the major product formed from the DNA-reactive metabolites is a 
DNA lesion known as -(deoxyguanosin-8-yl)-1-aminopyrene (dGAP).  This lesion has been 
shown to be mutagenic in bacterial and mammalian cells [12, 14].  The International Agency for 
Research on Cancer has classified 1-NP as a class 2B carcinogen [12, 14].  
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Scheme 1.1: Metabolism of 1-nitropryene via the nitroreduction pathway 
 Dpo4 was chosen to study the bypass of dGAP for a variety of reasons, including:  i) the 
kinetic mechanism of nucleotide incorporation into undamaged DNA was previously elucidated 
in the Suo laboratory [15], ii) many crystal structures of Dpo4 in ternary complexes that contain 
various lesions have been published [16-18], iii) Dpo4 is the only Y-family DNA polymerase 
encoded in the Sulfolobus sulfataricus genome, and thus would be responsible for most of its 
translesion DNA synthesis [19], and finally and most importantly iv) Dpo4 is a good model for 
eukaryotic Y-family DNA polymerases, like human DNA polymerase κ [20].  Studying Dpo4’s 
kinetic mechanism of bypass could provide insight into how eukaryotic Y-family DNA 
polymerases bypass dGAP.  To understand the bypass mechanism of a Y-family DNA 
polymerase catalyzing DNA synthesis opposite dGAP and to investigate the potential 
mutagenicity of 1-NP, an oligonucleotide was synthesized placing the dGAP single base lesion in 
a region rich in GCs.   Regions composed of repetitive DNA sequence have been shown to 
induce more mutations than non-repetitive regions [14, 21].  To understand the mechanism of 
 11 
bypass of the dGAP lesion catalyzed by Dpo4, pre-steady-state kinetic methods were utilized. 
 
Methods 
 Materials- For this project, OptiKinase from United Biochemical (Cleveland, OH), [γ-
32P]ATP from GE Healthcare, and nucleotides (dNTPs) from Invitrogen were purchased.  The 
full length Dpo4 was expressed in E. Coli and purified within the Suo laboratory as previously 
described [7]. 
 Synthetic Oligonucleotides-The DNA template 26-mer dGAP was synthesized as 
previously described [22].  Other DNA templates and primers (Table 1.1) were purchased from 
Integrated DNA Technologies (Coralville, IA) and purified using denaturing PAGE.  The 
concentration of these DNA oligonucleotides was determined using UV spectroscopy at 260 nm. 
Table 1.1 Sequences of DNA oligonucleotides 
Primers 
17-mer 5′-AACGACGGCCAGTGAAT-3′ 
19-mer 5′-AACGACGGCCAGTGAATTC-3′ 
20-mer 5′-AACGACGGCCAGTGAATTCG-3′ 
21-mer 5′-AACGACGGCCAGTGAATTCGC-3′ 
22-mer 5′-AACGACGGCCAGTGAATTCGCG-3′ 
23-mer 5′-AACGACGGCCAGTGAATTCGCGC-3′ 
Templates 
26-mer 3′-TTGCTGCCGGTCACTTAAGCGCGCCC-5′ 
a26-mer-dGAP 3′-TTGCTGCCGGTCACTTAAGCGCGCCC-5′ 
DA Trap 
D-1 (21/41-
mer) 
5′-CGCAGCCGTCCAACCAACTCA-3′ 
3′-GCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5′ 
a
G designates -(deoxyguanosin-8-yl)-1-aminopyrene (dGAP). 
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Radiolabeling and Annealing DA substrates-Each primer was 5’-32P-labeled by 
incubating it with Optikinase and [γ-32P]ATP for 3 hours at 37 ˚C.  These radiolabeled primers 
were annealed to either 26-mer or 26-mer-dGAP, unlabeled templates, at a molar ratio of 
1.00:1.15.  This mixture was heated to 75 ˚C for two minutes and then slowly cooled to room 
temperature. 
 Buffers: All pre-steady-state kinetic assays were performed in optimized buffer R (50 
mM HEPES, pH 7.5 at 37 ˚C, 5 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA, 5mM dithiothreitol, 
10% glycerol, and 0.1 mg/mL bovine serum albumin) [7, 15].  Electrophoresis mobility shift 
assays (EMSA) were performed in buffer S (50 mM Tris-Cl, pH 7.5 at 23 ˚C, 5 mM MgCl2, 50 
mM NaCl. 5 mM dithiothreitol, 10% glycerol, and 0.1 mg/mL bovine serum albumin).  The 
concentrations indicated above were those of the final mixed solutions. 
 Running Start Assay-The running start assay was performed as previously described [8, 
10]by a Jessica Brown, a colleague in the laboratory.  In brief, a solution of 5’-32P-labeled DNA 
(100 nM) and Dpo4 (100 nM) in buffer R was pre-incubated at 37 ˚C and subsequently rapidly 
mixed with a solution containing all four dNTPs (200 µM each) at 37 ˚C via a rapid chemical-
quench flow apparatus (KinTek).  The reaction was quenched with .37 M EDTA after various 
reaction times.  The reaction products were visualized by denaturing PAGE (17% 
polyacrylamide, 8 M urea).  
 EMSA- Dpo4 (0.5-80 nM) was titrated into a solution containing 5’-32P-labeled DNA 
(5nM) in buffer S at 23 ˚C.  To separate the free DNA from DNA complexed with Dpo4, native 
PAGE was performed at 70 V for 35 minutes at 23 ˚C using running buffer A (50 mM Tris 
acetate, pH 7.5, at 23 ˚C, 0.5 mM EDTA, 5.5 Mg(OAc)2).  After drying the gel, the bands were 
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quantitated using PhosphorImager 445 SI (Molecular Dynamics).   The dependence of the 
concentration of complexed Dpo4 and DNA (Dpo4·DNA) on the concentration of Dpo4 was fit 
using Equation 1.1 to yield Kd, DA,the equilibrium dissociation constant for the binary 
complex(Dpo4·DNA). 
  [Dpo4·DNA]= 0.5(Kd,DNA +E0+D0) – 0.5[Kd, DNA +E0+D0)
2 -4E0D0]
1/2  (Eq 1.1) 
In Equation 1.1, E0 is the active Dpo4 concentration and D0 is the DNA concentration. 
 Determination of Substrate Specificity – Pre-steady state single turnover dNTP 
incorporation assays were employed to determine the kp and Kd, dTP, where the kp is the 
maximum rate of incorporation of a dNTP and Kd, dTP is the equilibrium dissociation constant of 
an incoming nucleotide.  These assays were performed as previously described [7, 15].  In brief, 
a solution of 5’-32P-labeled DNA (30 nM) and Dpo4 (120 nM) in buffer R was pre-incubated at 
37 ˚C and subsequently mixed with solutions containing increasing amounts of a single dNTP.  
These reactions were quenched using the rapid-chemical quench or manually after various time 
points using 0.37 M EDTA.  The formed product was separated from the initial primer by 
denaturing PAGE (17% acrylamide, 8 M urea) and quantitated with a Phosphorimager 445 SI.  
For each concentration of dNTP, the function of product formation per time point was fit to a 
single exponential equation (Equation 1.2). 
 [Product] = A(1-exp(-kobs*t)) (Eq 1.2) 
Where kobs is the observed reaction rate constant, and A is the reaction’s product formation 
amplitude.  Next, the values of the kobs were plotted against the concentration of dNTP for the 
respective reaction.  This relationship was fit to a hyperbolic equation (Equation 1.3). 
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 kobs= kp[dNTP]/{[dNTP] + Kd, DA} (Eq 1.3) 
Where, as stated previously, kp is the maximum rate of dNTP incorporation, and the Kd,dTP is the 
dissociation constant for the ternary complex (Dpo4·DNA·dNTP) at equilibrium.  The substrate 
specificity is the ratio of the kp over the Kd,dTP. 
Biphasic Kinetic Assay- Shanen Sherrer, a colleague in the Suo laboratory, performed the 
biphasic kinetic assay.  In short, a pre-incubated solution of Dpo4 (120 nM) and 5’-32P-labeled 
DNA (30 nM) in buffer R was rapidly mixed with 5 µM DNA trap D-1 (Table 1.1) [7] and 1.2 
mM correct dNTP in buffer R.  After various time points, the mixture was quenched with 0.37 M 
EDTA.  The reaction products were separated using PAGE and visualized using the 
Phosphorimager 445 SI.  The product formation versus reaction time was fit using a double-
exponential equation (Equation 1.4): 
 [Product] = E0A1[1-exp(-k1t)] + E0A2[1-exp(-k2t)] (Eq 1.4) 
Where E0 is the active concentration of Dpo4, A1 and A2 are the reaction amplitudes of the two 
phases, and k1 and k2 are the rate constants for the two phases.  
Results 
 Running Start Assay- A running start assay was performed to observe the DNA 
polymerization pattern of Dpo4 in the presence of a dGAP lesion in the DNA substrate (17/26-
mer-dGAP) and to compare the polymerization with a controlled DNA substrate (17/26-mer).  As 
demonstrated previously, Dpo4 synthesized full-length product 26-mer with the undamaged 
DNA substrate 17/26-mer (Table 1.1) within 10 s (Figure 1.1A) [10].  While, Dpo4 was capable 
of synthesis bypassing the dGAP lesion, the enzyme was significantly slowed and full-length 
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product was not observed until after 180 s (Figure 1.1B).  Interestingly, during synthesis, an 
accumulation of intermediate products, 20- and 21-mer, indicated that Dpo4 stalled in its dNTP 
incorporation directly opposite the dGAP lesion and in the extension of the lesion bypass product, 
respectively.  No pausing was demonstrated in the DNA synthesis opposite the control template.  
In Figure 1.1A, formation of the 27-mer was likely due to blunt end addition [23], while 
accumulation of 24 and 25-mer in Figure 1.1A and 25-mer in Figure 1.1B was likely caused by 
polymerase “slippage” via primer realignment. 
 
Figure 1.1: Running start assay for Dpo4. (A) 17/26-mer; (B) 17/26-mer-dG
AP
. Sizes of 
important products are indicated, and the 21
st
 position marks the location of the dG
AP
 
lesion from the 3’-terminus of the DA template. 
 
 DA Binding of Dpo4 Effected by dGAP-The accumulation of product at the pause sites in 
Figure 1.1B suggested that the presence of dGAP, a bulky lesion, may cause a weakening in the 
binding affinity of Dpo4 to the DNA.   To measure the binding affinity (1/Kd,DA) of DNA to 
Dpo4, EMSA was performed for both control and damaged DNA templates.  PAGE was utilized 
to separate the binary complex (DNA·Dpo4) from unbound DNA (Figure 1.2).  
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Figure 1.2: EMSA gel image. The binary complex of Dpo4•DA was separated from free 
DA by native PAGE.  
 
The concentration of the Dpo4·DNA complex was plotted against the total concentration of 
Dpo4 and fit to Equation 1.1.  This quantitation is exemplified in Figure 1.3, where the DNA 
substrate was the 20/26-mer-dGAP and the Kd,DA was determined to be 1.0 ± 0.1 nM.  An EMSA 
was used to determine the binding affinity of DNA and Dpo4 for the controlled and damaged 
DNA substrates as listed in Table 1.2.   As expected, Dpo4 bound to the different substrate sites 
of undamaged DNA with approximately the same binding affinity (3.1-4.0 nM).  In the presence 
of the damaged DNA substrates, a larger range of Kd,DA values was determined (1.0-4.4 nM).  
At the first pause site (20/26-mer-dGAP) a four-fold tighter binding was observed.  This 
tightening of the Dpo4·DNA complex could suggest that the dGAP moiety may interact directly 
with the active site residues of Dpo4.  Typically, though, an increase in binding affinity should 
facilitate processive polymerization and, thus, the tight binding of 20/26-mer-dGAP cannot 
account for the accumulation of 20-mer.  To further investigate the accumulation of 
intermediates in the vicinity of a DNA lesion, the microscopic kinetic parameters of dNTP 
incorporation, the maximum rate of incorporation (kp) and the dNTP binding affinity (1/Kd,DA),  
were studied.  
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Figure 1.3: EMSA plot. The binary complex’s concentration versus the total concentration 
of Dpo4. The data was fit to Eq 1.1. 
 
Table 1.2 Binding affinity of Dpo4 to damaged and 
control DNA substrates at 23 °C 
DA 
Substrate  
Damaged 
DA
a 
(nM) 
Control 
DA
b 
(nM) 
Affinity 
Ratio
c 
19/26-mer 2.7 ± 0.2 3.1 ± 0.5 1.2 
20/26-mer 1.0 ± 0.1 4.0 ± 0.2 4.0 
21/26-mer 4.4 ± 0.2 3.7 ± 0.2 0.8 
22/26-mer 2.6 ± 0.2 3.8 ± 0.6 1.5 
23/26-mer 4.0 ± 0.3 3.6 ± 0.5 0.9 
aDamaged DNA refers to those with template 26-
mer-dGAP in Table 1. 
bControl DNA refers to those with template 26-mer 
in Table 1. 
cCalculated as (Kd, DNA)Control/(Kd, DNA)Damaged. 
 
The Kinetics of a dG
AP
 lesion and its Effect on dTP Incorporation- In order to 
determine the kp and Kd,DA, we performed single dNTP incorporation assays under single-
turnover reaction conditions.  In this assay, a pre-incubated solution of Dpo4 (120 nM) and 5’-
32P-labeled DNA substrate are rapidly mixed with a dNTP and quenched at various time points 
with .37M EDTA. The products are then separated using PAGE. The product formation is then 
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plotted against time and fit to Equation 1.2 to determine the observed reaction rate (kobs) (Figure 
1.4).   The dependence of kobs on the concentration of the dNTP is then plotted and fit to 
Equation 1.3, which yields values for the kp and Kd, DA (Figure 1.5).  
 
 
Figure 1.4: Relationship of Product Formation versus Time. Each time course was fit to Eq 
1.2 to yield a kobs. 
 
 
 
 
 
 
Figure 1.5: The Plot of Observed Rate Constant against Concentration. The plot of kobs 
values against dCTP concentrations was fit to Eq 1.3 to produce a kp of 6.3 ± 0.3 s
-1
 and a 
Kd, dCTP of 682 ± 80 µM. 
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This single dNTP incorporation assay was performed for the series of DNA substrates 
representing the progression of Dpo4 as it approached, encountered, and bypassed the dGAP 
lesion.  This data is found in Table 1.3.  Besides performing these assays on the damaged 
substrates, we also performed them on the control template 26-mer in order to generate a 
comparison (Appendix 1).  
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Table 1.3 Kinetic parameters for single dNTP incorporation opposite template 26-mer-dGAP   
dTP 
Kd, dTP 
(µM) 
kp 
(s
-1
) 
(kp/Kd, dTP)damaged 
(µM
-1
s
-1
) 
Efficiency 
Ratio
a,b Fidelity
c
 Probability
d
 
19/26-mer-dGAP 
dGTP  187 ± 36 4.3 ± 0.3 2.3x10-2 1.1 - 99.8 
dATP  373 ± 81 (6.3 ± 0.5)x10-3 1.7x10-5 0.8 7.4x10-5   0.1 
dCTP  227 ± 23 (6.4 ± 0.2)x10-3 2.8x10-5 5 1.2x10-3   0.1 
dTTP  1180 ± 190 (1.0 ± 0.1)x10-2 8.7x10-6 1.0 3.8x10-4   0.0 
*20/26-mer-dGAP 
dCTP  167 ± 15 1.03 ± 0.03 6.2x10-3 9.2 - 98.4 
dATP    856 ± 184 (7.6 ± 0.8)x10-2 8.9x10-5 0.2 1.4x10-2   1.4 
dGTP    955 ± 160 (2.0 ± 0.2) x 10-3 2.1x10-6 21 3.3x10-4   0.0 
dTTP  557 ± 36 (5.5 ± 0.1)x10-3 9.9x10-6 8.4 1.6x10-3   0.2 
*21/26-mer-dGAP 
dGTP    674 ± 231 (2.8 ± 0.3)x10-2 4.2x10-5 88 - 88.6 
dATP    886 ± 145 (2.7 ± 0.2)x10-3 3.1x10-6 0.8 6.8x10-2   6.5 
dCTP  328 ± 79 (6.8 ± 0.5)x10-4 2.1x10-6 15 4.7x10-2   4.4 
dTTP  2300 ± 461 (4.9 ± 0.7)x10-4 2.2x10-7 8.2 5.1x10-3   0.5 
22/26-mer-dGAP 
dCTP  682 ± 80 6.3 ± 0.3 9.3x10-3 3.7 - 99.8 
dATP  826 ± 85 (4.2 ± 0.2)x10-3 5.0x10-6 0.8 5.4x10-4   0.1 
dGTP  502 ± 98 (4.3 ± 0.3)x10-3 8.6x10-6 0.8 9.3x10-4   0.1 
dTTP  1540 ± 257 (4.7 ± 0.5)x10-3 3.1x10-6 3.6 3.3x10-4   0.0 
 23/26-mer-dGAP 
dGTP    62 ± 18 1.9 ± 0.1 3.1x10-2 0.8 - 98.9 
dATP    668 ± 173 (3.7 ± 0.4)x10-2 5.5x10-5 0.3 1.8x10-3   0.2 
dCTP  1130 ± 161 (9.0 ± 0.7)x10-3 7.9x10-6 0.2 2.6x10-4   0.0 
dTTP  1290 ± 218 (3.4 ± 0.3)x10-2 2.7x10-4 0.01 8.7x10-4   0.9 
aCalculated as (kp/Kd, dNTP)control/(kp/Kd, dNTP)damaged.    
bThe values for (kp/Kd, dNTP)control are from Supplementary Table 1.
 
cCalculated as (kp/Kd, incorrect dNTP)damaged/[(kp/Kd, correct dNTP)damaged + (kp/Kd, incorrect dNTP)damaged] 
dCalculated as {(kp/Kd, dNTP)damaged/[Σ(kp/Kd, dNTP)damaged]}x100. 
*Denotes pause sites. 
 
 By combining the measured kp and Kd, DA, the dNTP incorporation efficiency (kp/Kd,DA), 
efficiency ratio (relative to undamaged DNA), fidelity, and probability (Table 1.3) were 
calculated.  Comparing the kinetic data for non-pause sites, the kp/Kd,DA values for the correct 
dNTP incorporation were within 1-4-fold of the values for the control 26-mer and were 100-
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4000-fold greater relative to misincorporations (Table 1.3).  However, for the pause sites, 20/26-
mer-dGAP and 21/26-mer-dGAP, the correct dNTP incorporation efficiencies, respectively, 
decreased by 9- and 88-fold (Table 1.3) in comparison to the corresponding control DNA 
substrates.  Thus, the presence of the dGAP lesion unfavorably impacted the correct incorporation 
both opposite the lesion and in the extension of the bypass product.  
 The kinetic parameters also provided insight into the fidelity of DNA synthesis at each 
position along the damaged DNA template.  The fidelity ranged from 10-3 to 10-5, upstream and 
downstream of the pause sites, which is similar to Dpo4’sfidelity replicating control DNA.  In 
contrast, the fidelity at the pause sites, especially the 2nd pause site, was lowered by 10-100-fold 
compared with non-pause sites and with the control DNA. Based on the dNTP incorporation 
efficiency values in Table 1.3, Dpo4 catalyzed the insertion of dNTPs with the following 
preference: dCTP>>dATP>dTTP, dGTP at the first pause site and dGTP>dATP,dCTP>dTTP at 
the second pause site.  
 Biphasic Kinetics of dTP Incorporation at the Pause Site- A colleague in the lab 
investigated if incorporation of dNTPs at the pause sites demonstrated biphasic kinetics, which 
would be hidden in the previously performed single-turnover dNTP assays.   In order to separate 
the multiple kinetic phases, a DNA trap was added to the assay.  For these assays, a 5 µM 
concentration of undamaged D-1 (Table 1.1) was used as a trap.  To identify biphasic kinetics, a 
pre-incubated solution of Dpo4 (120 nM) and 5’-32P-labeled DNA (30 nM) was rapidly mixed 
with a solution containing the correct dNTP (1.2 mM) and unlabeled D-1 DNA substrate(5 µM) 
for various times before terminating the reaction by quenching with 0.37 M EDTA.  The time 
courses (Figure 1.6) of correct dNTP incorporation into 20/26-mer-dGAP and 21/26-mer-dGAP, 
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the positions of the two pause sites, were both biphasic and were fit to Equation 1.4, which 
yielded the biphasic  kinetic parameters listed in Table 1.4.  
 
Figure 1.6 Biphasic kinetics of correct nucleotide incorporation in the presence of a DA 
trap. The product concentration was plotted as a function of reaction time for each DA 
substrate which was then fit to Eq 1.4. 20/26-mer-dG
AP
 (•) or 21/26-mer-dG
AP
 (●).  
 
Table 1.4. Biphasic kinetic parameters for correct dNTP incorporation 
into 5′-[32P]-labeled DNA (30 nM) in the presence of a DNA trap (5 µM) 
at 37 °C.  
DA 
Substrate 
 
Correct 
dTP 
A1  
(nM) 
k1  
(s-1) 
A2  
(nM) 
k2  
(s-1) 
19/26-mer 
 
dGTP 27 ± 1 3.2 ± 0.4   
(91%)*    
20/26-mer 
 
dCTP 26 ± 1 4.6 ± 0.5   
(86%)*    
21/26-mer  
 
dGTP 27.0 ± 0.4 2.3 ± 0.1   
(88%)*    
19/26-mer-
dGAP 
dGTP 27.0 ± 0.4 2.5 ± 0.2   
(89%)*    
20/26-mer-
dGAP 
dCTP 2.0 ± 0.7 11 ± 6 18 ± 1 0.7 ± 0.1 
(6.7%)*  (60%)*  
21/26-mer-
dGAP 
dGTP 
0.9 ± 0.1 1.9 ± 0.3 5.7 ± 0.2 
0.031 ± 
0.003 
(3%)*  (19%)*  
*Calculated as (reaction amplitude/30 nM) x 100. 
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For the two pause sites, the rate of the first phase (k1) was faster than the rate of the second phase 
(k2), though the reaction amplitude of the first phase (A1) was smaller than the amplitude of the 
second phase (A2).  Moreover, the total amplitudes (A1 +A2) at these sites were much less than 
100% product formation.  For the 20/26-mer-dGAP, the total amplitude was 66.7%, while the 
21/26-mer-dGAP had a total amplitude of 22%. The control substrates and the 19/26-mer-dGAP 
demonstrated only monophasic kinetics and had reaction amplitudes close to 90%.  Thus, it was 
demonstrated through these DNA trap assays that the dGAP lesion only altered the kinetics of 
dNTP incorporation at the two critical steps of translesion synthesis.   
 
Discussion 
 The full length product seen in the running start assay (Figure 1.1B) demonstrated that 
Dpo4 is capable of bypassing a site-specifically placed dGAP lesion.  However, the initial 
formation of this full-length product was significantly slower with the damaged template, 26-
mer-dGAP, (180 s) than with the control template, 26-mer, (10 s).  Even yet, the accumulation of 
intermediates 20- and 21-mer indicated pausing of Dpo4 when incorporating dNTPs opposite the 
lesion and in the extension of the bypass product.  To determine the kinetic impact of the dGAP 
lesion on DNA binding and dNTP incorporation at positions upstream, opposite, and 
downstream of the lesion, we utilized EMSA and pre-steady-state kinetic methods. 
 A Kinetic Basis for the Pausing of Dpo4 in the Presence of dGAP- Figure 1.1B 
demonstrated the accumulation of two intermediates, the 20- and 21-mer, which indicated a 
 24 
stalling of Dpo4 at these sites on the damaged template. This incorporation profile can be 
explained through a comparison of the catalytic efficiencies of the positions leading up to full 
product formation, where the accumulation of 25-mer is considered full length product.  For 
example, incorporation of the correct dGTP into 21/16-mer-dGAP is 150-fold less efficient than 
correct dCTP into 20/26-mer-dGAP, which is subsequently 4-fold less efficient than correct dGTP 
into 19/26-mer-dGAP.  These inefficiencies of incorporation led to the accretion of 20- and 21-
mer with the later accumulating more than the former.  In contrast, incorporation of dGTP into 
the 23/26-mer-dGAP was 3-fold less efficient than incorporation of dCTP into the 22/26-mer-
dGAP, which was 220-fold more efficient than incorporation of dGTP into the 21/26-mer-dGAP.   
Thus, no accumulation was found for the 22- and 23-mer. In general, if a polymerase stalls at a 
site, its elongation is less efficient than its production.  The contrary is true of intermediates that 
do not show pausing through the accumulation at a nonproduct position.  
The efficiency ratio compares the incorporation efficiencies of the control over the 
damaged substrates.  As previously stated these substrate specificities combine the values of the 
kp and the Kd,dTP.  Thus, to determine which microscopic kinetic parameter contributed to the 
accumulation of the intermediate DNA substrate, the kp and the Kd,dTP for each site along the 
DNA template were compared to values of the control at the corresponding position (Figure 1.7 
and Figure 1.8).  
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Figure 1.7: dG
AP
 lesion’s effect on kp of correct nucleotide incorporation catalyzed by 
Dpo4. 
 
Figure 1.8: dG
AP
 lesion’s effect on KD, DA  of correct nucleotide incorporation catalyzed by 
Dpo4. 
 
 Figure 1.7 demonstrates that the kp was significantly affected only at the two pause sites (11-fold 
for 20/26-mer-dGAP and 58-fold for 21/26-mer-dGAP) though, the Kd,dTP values were within 5-
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fold of the control (Figure 1.8).  Thus, the inefficiency of dNTP incorporation at the pause sites 
was primarily due to a decrease in the kp.   
 DNA trap assays were performed to determine if the slow kp values were a result of DNA 
being ensnared in nonproductive complexes with Dpo4.  The results of the trap assay supported 
this hypothesis in that the pause sites demonstrated biphasic kinetics, whereby a small, fast phase 
(A1 and k1) proceeded a large, slow phase (A2 and k2).  The combination of the two phases 
distinguished in the DNA trap assay were close to the calculated kobs estimated in the single 
turnover experiments for both the 20- and 21/26-mer-dGAP.  In contrast, the DNA trap 
experiments with 19/26-mer-dGAP revealed only one fast kinetic phase for the incorporation of 
dGTP.  This data suggests that the dGAP lesion did not affect nucleotide incorporation at a non-
pause site and that both 19/26-mer-dGAP and the control substrates were bound to Dpo4 in a 
productive manner.  In comparison, the small fast phases of dNTP incorporation with both the 
20/26-mer-dGAP and the 21/26-mer-dGAP occurred with similar rates (k1, Table 1.4) to the single-
turnover rates observed with the control DNA substrates (Table 1.3).  Thus, small percentages 
(A1) of these DNA substrates were bound productively by Dpo4 (E·DNA
P
n ) in the fast phase. In 
the slow phase, larger percentages (A2) of the DNA substrates must have been bound in a less 
catalytically efficient mode by Dpo4 (E·DNANn), because they were elongated with much slower 
rates (k2).  Moreover, the elongation of E·DNA
N
n occurred in a single binding event, 
demonstrating that a slow conversion from E·DNANn to E·DNA
P
n must take place, followed by a 
rapid extension (k1).  The total reaction amplitudes of the 20/26-mer-dG
AP (66.7%) and the 
21/26-mer-dGAP (22%) had much smaller reaction amplitudes than the amplitudes of the 19/26-
mer-dGAP and control substrates (≈90%).  The partitioning between the dissociation of E·DNANn 
and the conversion of E·DNANn to E·DNA
P
n led to a reduction in A2 by a factor of k2/(k2 +koff), 
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where koff is the DNA dissociation rate from Dpo4·DNA.  The koff of D-1 (Table 1.1) was 
previously determined to be 0.02 s-1. This value was used for the koff of both the 20/26-mer-dG
AP 
and the 21/26-mer-dGAP because Dpo4 bound to these substrates with tighter or similar affinities 
as control DNA (Table 1.2). Using the estimated and determined koff, k2, A1, and A2 values, we 
estimated that 62% of 20/26-mer-dGAP and 31% of 21/26-mer-dGAP are in the form of E·DNANn 
and that 21.3% of 20/26-mer-dGAP and 56% of 21/26-mer-dGAP were never elongated. Thus, 
significant amounts of 20/26-mer-dGAP and 21/26-mer-dGAP were bound by Dpo4 in a 
catalytically incompetent mode (E·DNADn).  Overall, these DNA trap experiments suggest a 
kinetic mechanism for bypassing dGAP as shown in Figure 1.9. 
 
 
Figure 1.9: Proposed kinetic mechanism for the bypass of dG
AP
 catalyzed by Dpo4. 
 This proposed mechanism for lesion bypass is supported by existing structural evidence.  
For example, the combined NMR molecular mechanics computational studies reveal that the 
dGAP moiety of an embedded dGAP:dC base pair in an 11-mer duplex is only intercalated into the 
DNA helix between adjacent Watson-Crick base pairs [24].  Due to the syn glycosidic torsion 
angle, both bases of the dGAP:dC base pair are displaced into the major groove [24].  If dGAP at 
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the pause sites maintains this conformation, then the dGAP lesion will occupy the position of the 
incoming dNTP, thereby blocking catalysis.  This binary complex could not undergo synthesis 
without undergoing dramatic structural changes and likely represents the E·DNADn.  Other 
studies using x-ray crystallography, suggest the presence of other conformations in which the 1-
AP is quasi-intercalative or externally bound [11, 25].In one study, the AAF of damaged DNA is 
situated within the major groove open pocket and pairs with the dCTP with modest polymerase 
perturbation [26].  This conformation seems to indicate that the translocation of the little finger 
of Dpo4 would be hindered.  In another study of BPDE, there are two conformations of BPDE, 
one intercalated between base pairs and another flipped out of the DNA helix into a gap between 
the little finger and core domains [11, 25].  When the BPDE is intercalated, the distance between 
the 3’-OH of the primer is 9 Å, whereas when the BPDE is flipped out the distance is 3.9 Å.   
The optimum distance for catalysis is 3.4 Å [25].  Thus, extending this analysis to the dGAP 
studies, if the dGAP is flipped out the molecules of Dpo4·20/26-mer-dGAP will be in the form of 
E·DNAPn.  Contrastingly, if the dG
AP is quasi-intercalated, the same binary complex will require 
structural change to establish a conformation in which efficient catalysis can occur, and thus is 
likely in the form E·DNANn.  However, to verify and clarify this structural analysis, a 
collaborator of the Suo laboratory is working to crystallize the structure of Dpo4·DNA-dGAP. 
 Unique Enhancement of  DA Binding- Interestingly, our EMSA studies of DNA binding 
reported in Table 1.2 showed that Dpo4·20/26-mer-dGAP is about 4-fold tighter than 
Dpo4·21/26-mer-dGAP, and Dpo4·20/26-mer is the only binary complex affected by the lesion.  
This increased binding suggests that the dGAP in the Dpo4·20/26-mer-dGAP likely interacts with 
the residues of the little finger domain of Dpo4, which correlates with the structures of Dpo4 and 
BPDE-dG [11].  Usually DNA lesions tend to distort the DNA structure and weaken the binding 
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of DNA to a DNA polymerase [10].  However, the presence of the dGAP lesion tightened the 
binding between Dpo4 and the DNA substrate, which may explain why the 20/26-mer-dGAP was 
elongated with 150-fold higher efficiency than 21/26-mer-dGAP. 
 The Effect of dGAP on dTP incorporation at Adjacent Sites- The kinetic data found in 
Table 1.3 shows that dGAP did not kinetically affect dNTP incorporation at any downstream 
position of the pause sites. In contrast, both an abasic site and a cisplatin-d(GpG) adduct 
kinetically affected six to seven downstream dNTP incorporation during translesion synthesis 
catalyzed by Dpo4 [8, 10].  These differences could be a reflection of how each lesion distorts 
the structure of DNA within a DNA polymerase active site.  
 Final Conclusions about the Kinetic Mechanism of DA Lesion Bypass- The bisphasic 
kinetics of dNTP incorporation at pause sites have been observed in the bypass of an abasic site 
catalyzed by Dpo4 [8]as well as a cisplatin-d(GpG) adduct catalyzed by Dpo4  [10].  As with the 
bypass of dGAP, the total reaction amplitude in each of these cases is much less than the reaction 
amplitude obtained with either a control DNA or a DNA substrate at a non-pause site, indicating 
the existence of the E·DNADn form.  Some of these dead end binary complexes can bind a 
nucleotide and form dead-end binary complexes.   
 In conclusion, we have determined that Dpo4 is capable of bypassing a model single-base 
lesion dGAP in a kinetically inefficient and error prone manner.  The extension step rather than 
insertion opposite the dGAP lesion was more challenging for the enzyme.  Through this study, we 
have established the first kinetic mechanism for the dGAP lesion bypass. 
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Chapter 2: Determination of the Mutagenic Profile of Y-family DA 
Polymerases Bypassing a 1-itropyrene Induced Lesion 
Background and Introduction 
 The recently discovered Y-family DNA polymerases have been shown to function 
primarily in the bypass of replication stalling DNA lesions.  In overcoming DNA lesions, these 
DNA polymerases reduce the possibility of cell apoptosis induced by DNA damage.  Moreover, 
the significance of these Y-family DNA polymerases is underscored by their presence in 
organisms in all three domains of life.  One such Y-family DNA polymerase is Sulfolobus 
sulfataricus’s DNA polymerase IV (Dpo4), which was described in depth in Chapter 1.  While 
Sulfolobus sulfataricus has only one Y-family enzyme, in humans, four Y-family DNA 
polymerases have been identified.  These polymerases are known as human DNA polymerases 
eta (hPolη), iota (hPolι), kappa (hPolκ), and Rev1.  Like most Y-family DNA polymerases, these 
enzymes are capable of both error-free and error-prone translesion synthesis in vivo.  However 
this process is dependent on the specific lesion present in the DNA.  For example, hPolη is 
responsible for the error-free bypass of cis-syn thymine-thymine (TT) dimers [27, 28].  Genetic 
mutational inactivation of hPolη leads to a cancer-prone syndrome known as xeroderma 
pigmentosum variant (XPV) that predisposes individuals to an increased incidence of sunlight-
induced skin cancer [28].  Besides the cis-syn TT dimers, hPolη has been shown to bypass a 
variety of DNA lesions, including abasic sites (AP sites) [29], 8-ozoguanini (8-oxoG) [29], (+)-
trans-anti-benzo[a]pyrene-2-dG ((+)BPDE-dG) [29], 1,N6-Ethenodeoxyadenosine [30], O6-
methylguanine [31], N-2-acetylaminofluorene-dG (AAF-dG) [32], and cisplatin-dGpG 
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intrastrand adducts [32].  In contrast, hPolι is the most error-prone human Y-family DNA 
polymerase known to date, but has been shown to traverse AP sites [33], 8-oxoG,AAF-dG[34] , 
cis-syn TT dimmers [35], and other TT photoproducts [36].  hPolκ is a member of the DinB 
subfamily and is the closest of the human Y-family DNA polymerases to Dpo4 [37].  hPolκ has 
been shown to bypass AP sites , 8-oxoG, AAF-dG, and (+)BPDE-dG [38].  Finally, Rev1, which 
is the only Y-family DNA polymerase to contain a BRCT domain, has been implicated in the 
mediation of protein-protein interactions and is classified as a dCTP transferase [39].  Human 
Rev1 has been shown to incorporate dCTP opposite AP sites [40], 8-oxoG [41], and (+)BPDE-
dG [41].  Based on the published studies, there is clearly significant overlap of the in vitro lesion 
bypass spectra for the four human DNA polymerases.  However, it is still unclear which Y-
family DNA polymerase bypasses specific lesions in vivo.    
 In chapter one, a specific lesion known as -(deoxyguanosin-8-yl)-1-aminopyrene (dGAP) 
which forms from a reaction between DNA and the metabolites of 1-nitropyrene (1-NP), was 
described and investigated.   The model Y-family DNA polymerase Dpo4 was shown capable of 
bypassing this lesion and the mechanism and fidelity of this bypass were determined.  However, 
to extend the study of the effect of the dGAP lesion on replication by Y-family DNA 
polymerases, we set out to gather DNA sequence data for Dpo4, as well as for two of the human 
Y-family DNA polymerases.   While kinetic analysis can provide insight into the fidelity of these 
enzymes, it cannot capture the full mutagenic profile of the Y-family DNA polymerase’s bypass 
of the dGAP lesion.  For example, kinetic analysis cannot capture infrequent mutation events or 
deletions and additions that could occur during dGAP bypass.   Thus, we exploited a novel 
experiment developed in our lab, short oligonucleotide sequencing assay (SOSA) [42], to 
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determine the mutational spectra of three Y-family DNA polymerases,  Dpo4, hPolκ, and hPolη .  
 
Methods 
Materials- T4 DNA Ligase and Taq DNA polymerase were purchased from Fermentas 
and Invitrogen, respectively.  [γ-32P]ATP was purchased from GE Healthcare Life Sciences.  The 
oligonucleotides listed in Table 2.1 were purchased from Integrated DNA Technologies, and 
were purified, labeled, and annealed as previously described [15].  The TOPO TA Cloning Kit 
for Sequencing was purchased from Invitrogen.  Its contents were used in both the PCR and 
transformation steps. 
Table 2.1. Sequences of DNA oligonucleotides 
Primers 
17-merS 5’-CTACCTGAACGACGGCC-3’ 
18-merS 5′-GGTCAACATTGCACTAGC -3′ 
Templates 
26-mer                 3′-TTGCTGCCGGTCACTTAAGCGCGCCC-5′ 
a26-mer-dGAP 3′-TTGCTGCCGGTCACTTAAGCGCGCCC-5′ 
73-mer 
3′-CTACTCAGCCGTTGATGGACTTGCTGCCGGTCACTTA 
AGCGCGCCCCTGTCCTGCCGATCACGTTACAACTGG-5′ 
a73-mer-dGAP 
3′-CTACTCAGCCGTTGATGGACTTGCTGCCGGTCACTTA 
AGCGCGCCCCTGTCCTGCCGATCACGTTACAACTGG-5’ 
a
G designates -(deoxyguanosin-8-yl)-1-aminopyrene (dGAP). 
 
Protein Purification- My colleagues in Dr. Suo’s laboratory purified the proteins used for 
this study, which included Sulfolobus sulfataricus Dpo4, hPolη, and hPolκ.  The full length Dpo4 
was expressed in E. coli and purified within as previously described [7].   
For DNA polymerase η, the gene encoding the C-terminal His-tagged enzyme was cloned 
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into the deI and XhoI sites of pET21B to generate a plasmid pET-21B-hPolη. The C-terminal 
His6-tagged hPolη was induced and expressed in E. coli BL21(DE3) Rosseta cells at 16 °C. The 
protein was purified through a nickel affinity column, a heparin sepharose column, and a HiTrap 
SP column. The concentration of purified hPolη was measured spectrophotometrically at 280 nm 
using the calculated extinction coefficient of 70731 M-1cm-1. 
The gene encoding a truncated fragment (residues 9-518) of hPolκ (h∆Polκ) was 
subcloned into the coI and XhoI sites of a plasmid pHIS-Parallel1 (24) to create pHIS-
hPolkappa-9-518. This plasmid was transformed into E. coli BL21(DE3) Rosetta cells. The N-
terminal His6-tagged h∆Polκ was induced and expressed at 19 °C, and then was purified through 
a nickel affinity column, a heparin sepharose column, a HiTrap Q column, and a Sephacryl 200 
gel filtration column.  The concentration of purified h∆Polκ was measured 
spectrophotometrically at 280 nm using the calculated extinction coefficient of 31860 M-1cm-1. 
Buffer- The reaction buffer R contained 50 mM HEPES (pH 7.5 at 37 °C), 5 mM MgCl2, 
50 mM NaCl, 5 mM DTT, 10% glycerol, 0.1 mM EDTA, and 0.1 mg/ml BSA. All reactions 
were performed at 37 °C unless otherwise indicated. 
Running Start Assays- A running start assay was performed as previously described for 
each Y-family DNA polymerase studied [7, 10] .  In brief, a solution of 5’-32P-labeled 
DNA(17/26-mer-dGAP or 17/26-mer)(100 nM) and DNA polymerase (100 nM) in buffer R was 
pre-incubated at 37 ˚C and subsequently rapidly mixed with a solution containing all four dNTPs 
(200 µM each) via a rapid chemical-quench flow apparatus (KinTek).  The reaction was 
quenched with .37 M EDTA after various reaction times.  The reaction products were visualized 
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by denaturing PAGE (17% polyacrylamide, 8 M urea).  
 Short Oligonucleotide Sequencing Assay (SOSA)- Each Y-family DNA Polymerase (120 
nM) was pre-incubated with the DNA substrate (17/73-mer-dGAP or 17/73-mer)(30 nM, Table 1) 
and subsequently mixed with all four dNTPs (200 µM each) for an optimized time period at 37 
°C.  The reaction time was optimized to produce sufficient full length bypass product (60-mer) or 
near full length bypass product.  To terminate the reaction, the solution was treated with three 
cycles of freeze-thaw (-196 °C and 95 °C respectively) denaturation.  SOSA was performed 
using a control DNA substrate (17/73-mer) and Dpo4 to examine the quality of the method and 
to compare the mutagenic profile of Dpo4 under normal replications and in translesion synthesis.  
The mutagenicity of Dpo4, hpol η, and h∆pol κ's bypass of the dGAP lesion were determined by 
performing the SOSA with the 17/73-mer-dGAP.  This DNA template (73-mer-dGAP) contained a 
dGAP lesion 33 positions from the 5' end (Table 1).  After generating a population of “dGAP 
bypass product”, these products were isolated using PAGE, in which radiolabeled markers were 
utilized to determine the location of full length or near full length product.  The isolated products 
were purified as previously described [22].  Once purified, the products were amplified using 
polymerase chain reaction (PCR), utilizing Taq DNA polymerase, 17-merS and 18-merS (Table 
2.1).   These primers were designed to provide sequence information for 10 nucleotides upstream 
from the dGAP lesion and 12 nucleotides downstream from the lesion in addition to incorporation 
events directly opposite of the dGAP lesion.  Single dA’s were placed on the blunt ends of the 
double stranded DNA by Taq DNA polymerase during the PCR step.   After amplification, the 
population of “bypass product” was ligated into a pCR4-TOPO vector using a TOPO TA cloning 
kit (Invitrogen) and subsequently transformed into a TOP10 strain of E. coli (Invitrogen) as 
previously described [42].  The DNA plasmid containing the ligated bypass product was 
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sequenced from bacterial colonies (Genewiz, South Plain, NJ).  This method is summarized in 
Scheme 2.1. 
 
Scheme 2.1: SOSA Overview 
Results 
Running Start Assays of three Y-family DA polymerases-While full-length Dpo4 and 
hPolη were utilized, recombinant h∆Polκ (residues 9-518) was used as the enzyme, rather than 
its full-length protein.  For the running start assays, these enzymes were expressed and purified 
from E. coli as soluble and active proteins.   
The running start assays were performed for each Y-family DNA polymerase under the 
same reaction conditions as described in the Materials and Methods.  The results for Dpo4’s 
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elongation past the dGAP adduct were seen in Figure 1.1 and described in the Chapter 1 Results 
section.  In brief, Dpo4 synthesized full-length product 26-mer with the undamaged DNA 
substrate 17/26-mer (Table 2.1) within 10 s (Figure 1.1A).  However, while Dpo4 was capable of 
synthesis bypassing the dGAP lesion, the enzyme was significantly slowed and full-length 
product was not observed until after 180 s (Figure 1.1B).  Interestingly, during synthesis, an 
accumulation of intermediate products, 20- and 21-mer, indicated that Dpo4 stalled in its dNTP 
incorporation directly opposite the dGAP lesion and in the extension of the lesion bypass product, 
respectively.   
The running start assay for h∆Polκ generated similar results to those of Dpo4.  h∆Polκ 
synthesized near full-length product (25-mer) with the undamaged DNA substrate 17/26-mer 
(Table 2.1) within 3 s (Figure 2.1A).  However, in bypassing the dGAP lesion, h∆Polκ was 
significantly slowed and the 25-mer was not observed until 30 s (Figure 2.1B).  Accumulation of 
the 25-mer rather than the 26-mer in Figure 2.1A and Figure 2.1B was likely caused by 
polymerase “slippage” via primer realignment.  Moreover, like Dpo4, the accumulation of 
intermediate products, 20- and 21-mer, indicated stalling in dNTP incorporation directly opposite 
the dGAP lesion and in the extension of the lesion bypass product, respectively.  Again, no 
pausing was demonstrated in the DNA synthesis opposite the control template.   
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Figure 2.1: Running start assay for hIPolκ. (A) 17/26-mer; (B) 17/26-mer-dG
AP
. Sizes of 
important products are indicated, and the 21
st
 position marks the location of the dG
AP
 
lesion from the 3’-terminus of the DA template. 
 
In contrast to Dpo4 and h∆Polκ, the running start assay for hPolη showed the generation 
of full-length product (26-mer) in 3 s for both the of 5’-32P-labeled control (17/26-mer) and 
damaged DNA substrate (17/26-mer-dGAP) (Figure 2.2A and B).  In Figure 2.2A and B, 
formation of the 27-mer was likely due to blunt end addition [23].  Even more interesting to the 
rate of bypass, hPolη does not seem to have the same pausing pattern as Dpo4 and h∆Polκ.  In 
fact, hPolη does not seem to pause at all when bypassing and extending synthesis past the dGAP 
lesion.  However, in general, there do seem to be more of an accumulation of intermediates for 
the replication of the damaged template versus the control.  
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Figure 2.2: Running start assay for hPolη. (A) 17/26-mer; (B) 17/26-mer-dG
AP
. Sizes of 
important products are indicated, and the 21
st
 position marks the location of the dG
AP
 
lesion from the 3’-terminus of the DA template. 
 
Thus, both Dpo4 and h∆Polκ were able to bypass the dGAP .  However, their rate of 
incorporation slowed when encountering this lesion and extending the bypass product.  At these 
two pause sites, the incorporation profile indicated accumulation of intermediate products 20-
mer and 21-mer, suggesting slow turnover at these sites in comparison to the corresponding 
assay performed with 17/26-mer.  Furthermore, the accumulation at the second pause site was 
greater than that at the first pause site, indicating that it was more of an enzymatic challenge to 
extend past the incorporation opposite the lesion than to perform that incorporation itself.  In 
contrast to Dpo4 and h∆Polκ, hPolη bypassed the dGAP site relatively efficiently and subsequent 
downstream incorporation was not significantly perturbed by the lesion.  However, while there 
was no obvious difference in the amount of time required for hPolη to generate the full-length 
product with the control and damaged template, in general, there was more accumulation of 
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intermediates for the damaged template.    
These running start assays will be used to analyze the mutagenic profiles.  However, the 
template used for the SOSA assay was the 17/73-mer-dGAP.  Thus, in the future the running start 
assays will be performed with the 17/73-mer-dGAP in order to better compare the results with 
those of the SOSA assay.  
Quantitative analysis of the mutagenic profiles of Dpo4 synthesis of the control template- 
In order to confirm the quality of the SOSA method and to ensure mutations were not due to 
sequence bias, SOSA was performed on undamaged 73-mer with Dpo4.  Among the 52 colonies 
sequenced, there were only two single-base deletions and two base substitutions (Figure 2.3).  
The total error frequency (4 mutations/ (25 nucleotides x52 incorporation events)) of Dpo4 was 
calculated to be 3x10-3, which corresponds to the fidelity determined by pre-steady state kinetic 
assays in Chapter 1 (10-3-10-5).  
Cytosine Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCGCGCGGGGACAGGACGGCTAGTGCAATGTTGACC     (48/52) 
                 C                                                (1/52) 
                        C                                         (1/52) 
                    G                                             (1/52) 
 
o Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCG-GCGGGGACAGGACGGCTAGTGCAATGTTGACC      (1/52)  
 
Figure 2.3: Mutagenic profile for Dpo4’s replication of 17/73-mer.  Results from the SOSA 
are shown separately based on specific nucleotide incorporated by Dpo4 in the control 
template.   Sequences corresponding to primers used for amplification are shown in lower-
font while sequenced nucleotides are upper font and underlined.  Individual base 
substitutions (blue), deletions (red), and additions (green) are shown.  Cyan highlighted 
font indicates position where the lesion will be in the 17/73-mer-dG
AP
. 
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Quantitative analysis of the mutagenic profiles of dG
AP
 lesion bypass catalyzed by Dpo4, 
h;Polκ, and hPolη- Due to the fact that single nucleotide kinetic analysis of the incorporation 
events in the vicinity of the dGAP lesion may not accurately reflect all of the possible catalytic 
transactions occurring in this region of the DNA substrate, we applied SOSA to determine the 
precise sequence of DNA synthesized by each Y-family DNA polymerase.  Although the DNA 
synthesis rates for each enzyme vary, we optimized the time for each enzyme to generate the 
full-length bypass products and thus encompassed the entire bypass product, including the initial 
approach of the enzyme to the lesion, its bypass, and subsequent extension.  The SOSA was 
designed to provide sequence information for 10 nucleotides upstream from the dGAP lesion and 
12 nucleotides downstream from the lesion in addition to incorporation events directly opposite 
of the dGAP. 
 The sequencing spectra for Dpo4’s bypass of the dGAP lesion can be found in Figure 2.4.  
Results for Dpo4 revealed that 90% of the bypass products (47/52 colonies) are characterized by 
an incorporation of dCTP opposite the lesion.   In addition, Dpo4 incorporated an incorrect 
dATP (2%) and generated a deletion at the site of the lesion (8%).  As the running start assay 
indicated, there was significant stalling of Dpo4 not only when incorporating nucleotides 
opposite the lesion, but also in extending the product one base pair downstream of the lesion.  
Thus, it is important to analyze the mutagenic profile of this downstream position.  For Dpo4, 
90% of the bypass products contained a dGTP at the position one base pair downstream from the 
lesion.    Mutations at the downstream position included two substitutions and two deletions.  
Besides the mutations corresponding to the pause sites of Dpo4, random mutations were 
generated both upstream and downstream of the lesion (Figure 2.4).  Thus of the 90% of those 
sequences with a correct incorporation opposite the lesion, 23% included mutations, either 
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deletions or substitutions, primarily upstream of the lesion or at the site directly downstream of 
the lesion.  Overall, not including mutations opposite the lesion site, 27% of the bypass products 
contained mutations.   
 
Cytosine Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCGCGCGGGGACAGGACGGCTAGTGCAATGTTGACC      (36/52) 
                            C                                      (1/52) 
                            A                                      (2/52) 
                   C                                               (1/52) 
                          C                                        (1/52) 
                    A                                              (1/52) 
                        T                                          (1/52) 
                      A                                            (1/52) 
                         A                                         (1/52) 
                                      A                            (1/52) 
                          T                                        (1/52) 
                         
 
o Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCG-GCGGGGACAGGACGGCTAGTGCAATGTTGACC       (0/52) 
                        C                                          (1/52) 
 
 
 
 
Adenine Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCGAGCGGGGACAGGACGGCTAGTGCAATGTTGACC       (2/52) 
                            G                                      (2/52)  
Figure 2.4: Mutagenic profile for Dpo4’s replication of 17/73-mer-dG
AP
.  Results from the 
SOSA are shown separately based on specific nucleotide incorporated by Dpo4 in the 
control template.   Sequences corresponding to primers used for amplification are shown in 
lower-font while sequenced nucleotides are upper font and underlined.  Individual base 
substitutions (blue), deletions (red), and additions (green) are shown.  Cyan highlighted 
font indicates position of the lesion. 
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 As demonstrated in the sequencing spectra (Figure 2.5) h∆Polκ lacked a strong 
preference in incorporating nucleotides opposite the dGAP lesion.   The polymerase incorporated 
the correct dCTP (38%), an incorrect dATP (28%), an incorrect dTTP (2%), and caused a 
deletion at this site (33%).  Moreover, h∆Polκ incorporated the correct dGTP in 84% in 
extending past the incorporation at the site of the lesion.   Of the mutations produced at this site, 
71% were deletions and 29% were substitutions.   h∆Polκ’s bypass products were also associated 
with mutations both upstream and downstream of this lesion (Figure 2.5).  Not including stands 
that had a mutation only at the lesion site, 49% of the bypass strands from h∆Polκ had mutations.  
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Cytosine Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCGCGCGGGGACAGGACGGCTAGTGCAATGTTGACC (9/45) 
                                 C    C                      (1/45) 
                               T                             (2/45) 
                         A   GA   ACAGG                      (1/45) 
                            T                                (1/45) 
                              GG                             (1/45) 
                      G              T                       (1/45) 
                      AT  G G                                (1/45) 
 
 
 
o Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCG-GCGGGGACAGGACGGCTAGTGCAATGTTGACC (7/45) 
                            G                                (3/45) 
                            G      T                         (1/45) 
                              G                              (1/45) 
                         C                                   (1/45) 
                     C                                       (2/45) 
 
 
 
Adenine Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCGAGCGGGGACAGGACGGCTAGTGCAATGTTGACC (7/45) 
                   T                A                        (1/45) 
                                  G                          (1/45) 
                        G                                    (1/45) 
                            A                                (1/45) 
                                        G                    (1/45) 
 
 
Thymine Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCGTGCGGGGACAGGACGGCTAGTGCAATGTTGACC (0/45) 
                              G                              (1/45)  
Figure 2.5: Mutagenic profile for hIPolκ’s replication of 17/73-mer-dG
AP
.  Results from 
the SOSA are shown separately based on specific nucleotide incorporated by Dpo4 in the 
control template.   Sequences corresponding to primers used for amplification are shown in 
lower-font while sequenced nucleotides are upper font and underlined.  Individual base 
substitutions (blue), deletions (red), and additions (green) are shown.  Cyan highlighted 
font indicates position of the lesion. 
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Like h∆Polκ, hPolη lacked a strong preference in incorporating nucleotides opposite the dGAP 
lesion.  As represented in its sequencing spectra (Figure 2.6), the polymerase incorporated the 
correct dCTP (36%), an incorrect dATP (11%), an incorrect dTTP (5%), an incorrect dGTP 
(2%), and generated a deletion at the site opposite the lesion (45%).  At the position directly 
downstream of the lesion, the correct dGTP was incorporated in 68% of the bypass products.  Of 
those products that hPolη induced a mutation at this site, 86% were deletions and 14% were 
substitutions.   hPolη also generated mutations both up and downstream of the lesion.  Not 
including mutations at the site of the lesion, 80% of the hPolη bypass products had mutations.  
These mutagenized bypass products included some in which hPolη generated large deletions (4 
or more consecutive nucleotides).   
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Cytosine Incorporations 
 
CTACCTGAACGACGGCCAGTGAATTCGCGCGGGGACAGGACGGCTAGTGCAATGTTGACC (5/44) 
                 G T           A                             (1/44) 
                      G                                      (1/44) 
                    T                                        (1/44) 
                        G                                    (1/44) 
                                  AC                         (1/44) 
                    A                                        (1/44) 
                                      A                      (1/44) 
                                       G                     (1/44) 
                                  G                          (1/44) 
                            A                                (1/44) 
                      G      C                               (1/44) 
 
 
o Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCG-GCGGGGACAGGACGGCTAGTGCAATGTTGACC (2/44) 
                            AA          T                    (1/44) 
                             AAA                             (1/44) 
                 C                                           (1/44) 
                         CG                                  (1/44) 
                      G       GGGG T                         (1/44) 
                      G           ACAG                       (1/44) 
                            G                                (4/44) 
                        A   G        A                       (1/44) 
                            G      A                         (1/44) 
                      G CA  G                                (1/44) 
                     AATTCG G      T                         (1/44) 
                  A    TTCG G                                (1/44) 
                            G           G                    (1/44) 
                       A    G                                (1/44) 
                      G     G    G                           (1/44)  
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Adenine Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCGAGCGGGGACAGGACGGCTAGTGCAATGTTGACC (1/44) 
                                   C  GACG                   (1/44) 
                    G             G   GACG                   (1/44) 
                            A     ACAG  C                    (1/44) 
                              G                              (1/44) 
 
 
Thymine Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCGTGCGGGGACAGGACGGCTAGTGCAATGTTGACC (0/44) 
                      G C      A                             (1/44) 
                            AT                               (1/44) 
 
 
Guanine Incorporation 
 
CTACCTGAACGACGGCCAGTGAATTCGGGCGGGGACAGGACGGCTAGTGCAATGTTGACC (1/44) 
 
  
Figure 2.6: Mutagenic profile for hPolη’s replication of 17/73-mer-dG
AP
.  Results from the 
SOSA are shown separately based on specific nucleotide incorporated by Dpo4 in the 
control template.   Sequences corresponding to primers used for amplification are shown in 
lower-font while sequenced nucleotides are upper font and underlined.  Individual base 
substitutions (blue), deletions (red), and additions (green) are shown.  Cyan highlighted 
font indicates position of the lesion. 
 
 Bar graphs depicting the number and types of mutation at each site over all the 
sequencing spectra for each enzyme can be found in Appendix 2.  These graphs are useful for 
comparing the total mutations generated by each Y-family DNA polymerase and for visualizing 
the distribution of these mutations within the sequencing region.  
Discussion 
 The importance of the Y-family DNA polymerases has become apparent due to their 
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widespread ability to replicate damaged DNA.  Moreover, of the sixteen DNA polymerases 
identified in humans, four have been classified into this low-fidelity and error-prone family.  In 
our study, we analyzed the bypass capabilities of two human Y-family DNA polymerases as well 
as Dpo4, the most widely studied Y-family DNA polymerase.   It has become evident that, even 
within the same family, polymerases possess structural attributes that render their functions 
unique.  In vivo, different polymerases will be more likely than others to bypass a specific lesion.  
Thus, it is necessary to determine the bypass efficiencies and mutagenic profiles to surmise 
which polymerase would likely bypass a specific lesion in vivo.  As previously described, the 
mutagenic profile for each polymerase was determined using a novel experiment, known as 
SOSA. The efficiency of bypass and mutagenic profiles of hPolη and h∆Polκ were studied to 
determine which of these human DNA polymerase are more likely to bypass the dGAP lesion.  In 
addition, this data for the human Y-family DNA polymerases was compared to that of the model 
polymerase Dpo4, which is the sole Y-family DNA polymerase in Sulfolobus sulfataricus.  In 
future projects, the human Y-family DNA polymerases hpolι and hRev1 will be investigated to 
compare their bypass efficiencies and mutagenic characterization with those of the polymerases 
used in this study.    
Due to the interesting results from Chapter 1 as well as the predominance of 1-
nitropyrene as an environmental pollutant, we decided to determine the bypass ability and 
characterize the mutagenic profiles of Dpo4  and two human Y-family DNA polymerases with 
the dGAP lesion.  The results of the running start assay from Chapter 1 showed that despite a 
decreased rate in the formation of full-length product, Dpo4 was able to bypass the dGAP lesion.  
Moreover, we demonstrated that both hPolη and h∆Polκ were capable of bypassing this lesion 
and generate full-length product.  Interestingly, the running start assays for Dpo4 and h∆Polκ 
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revealed the same two strong pause sites, indicating that each of these enzymes stalled in the 
incorporating a nucleotide directly across from the lesion and at the next downstream position.  
Moreover, these enzymes had a similarly slowed rate after encountering the dGAP lesion.  In 
sharp contrast, the running start assay for hPolη revealed no distinct pausing when encountering 
the lesion and was only mildly perturbed in the rate of production of full-length product.  As 
Dpo4 is the only Y-family DNA polymerase in Sulfalobus sulfataricus, it is clearly the enzyme 
that would bypass the dGAP lesion in vivo.  However, in humans, one of the four Y-family DNA 
polymerases would most likely bypass this specific lesion.  Certainly, when comparing only the 
running start assays of hPolη and h∆Polκ, we would surmise that hPolη would more likely 
bypass the dGAP lesion in vivo.  This conclusion is based solely on hPolη’s lack of the significant 
stalling demonstrated by h∆Polκ and due to its rate of formation of full-length product in 
comparison to h∆Polκ. 
However, we collected more data regarding the bypass of the dGAP lesion that provided 
us with the precise DNA sequence synthesized by each DNA polymerase.  This data was 
collected via the implementation of SOSA, a novel assay developed in the Suo laboratory.  The 
SOSA experiment was tested by sequencing the replication of control 73-mer by Dpo4.  The 
sequencing results revealed only four sequences with errors, two were substitution and two were 
deletions.  As previously stated, this resulted in an error frequency that corresponded to the 
fidelity determined by pre-steady state kinetic assays in Chapter 1 (10-3-10-5).  Thus, we 
confirmed that SOSA was a valid way of sequencing the bypass products and determined that 
there was negligible sequence bias.  
 As described in the Results section, Dpo4 preferentially incorporated the correct 
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nucleotide, while h∆Polκ and hPolη tended to synthesize across from the lesion more 
indiscriminately.  A comparison of these three Y-family DNA polymerases and their DNA 
synthesis opposite the dGAP lesion is found in Figure 2.7.  Figure 2.7 makes it very clear how 
much more efficient Dpo4 is in its synthesis opposite the lesion in comparison to the human Y-
family DNA polymerases.  In comparing h∆Polκ and hPolη and their incorporation at the site of 
the lesion, they appear to have very similar tendencies to insert mutations rather than the correct 
nucleotide.  
 
Figure 2.7: Comparison of the synthesis opposite the lesion for Dpo4 (blue), hPolη (yellow), 
and hIPolκ (purple). 
 
Besides the incorporation opposite the lesion, the mutagenic profile of the extension of the 
bypass product directly one position downstream of the lesion was also analyzed (Figure 2.8).   
At this position, the three Y-family DNA polymerases are more likely to incorporate the correct 
nucleotide.  At this site, Dpo4 continues to generate the most accurate bypass products.  When 
comparing h∆Polκ and hPolη, h∆Polκ has a greater fidelity at this position than hPolη.  This 
decreased fidelity of hPolη is due to its increased tendency to generate a deletion at this position.  
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Finally, it is important to analyze and compare the overall fidelity of each polymerase.  
 
Figure 2.8: Comparison of the synthesis of the first downstream position after the dG
AP
 
lesion for Dpo4 (blue), hPolη (yellow), and hIPolκ (purple). 
 
Figures A2.1, A2.2, and A2.3 in the appendix depict the mutations at each position in the 
sequencing window for Dpo4, h∆Polκ, and  hPolη, respectively .  Quantitatively, Dpo4 has an 
overall fidelity of 0.01, while the fidelities of h∆Polκ and hPolη respectively are 0.06 and .11.  
Based on this study, the presence of the dGAP lesion decreases the fidelity of Dpo4 by only about 
ten fold.  Moreover, while hPolη seemed to have the greatest bypass efficiency based on the 
running start assay, its mutagenic profile is significantly worse than the other human Y-family 
DNA polymerase analyzed.  
Dpo4 is the only Y-family DNA polymerase in Sulfolobus sulfataricus and thus will be 
responsible for translesion synthesis across the dGAP lesion.   Fortunately, for this organism, it 
seems from our results that Dpo4 bypasses the lesion with comparatively good fidelity.  Unlike 
Sulfolobus sulfataricus, humans have four Y-family DNA polymerases.  The evolution of 
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numerous enzymes in the same organism may be to decrease the errors associated in this process 
by having polymerases that specialize in the bypass of a particular lesion.  This theory is 
supported by the fact that human Y-family DNA polymerases possess drastically different 
abilities to bypass different DNA lesions.  Thus, the results of this study can be used in an 
attempt to understand the precise mutagenic characterization of two human Y-family DNA 
polymerases in response to a specific lesion.  Despite its increased bypass efficiency, hPolη 
generated significantly more mutations than h∆Polκ.  Thus, based solely on the comparison of 
the mutagenic profiles it is more likely that h∆Polκ bypasses the dGAP lesion in vivo.  However, 
more studies must be done to analyze the other human Y-family DNA polymerases.  The method 
used in this study can be used in future studies to generate information regarding the mutagenic 
characterization of each Y-family DNA polymerase for a variety of DNA lesions. 
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Chapter 3: Antiviral Drugs as Substrates for X- and Y-family DA 
Polymerases 
Background and Introduction 
 In modern society, viral infection is one of the leading causes of disease.  While there are 
a plethora of different virally induced diseases, two stand at the forefront due to their widespread 
effect on human health.  Hepatitis B virus (HBV) causes severe liver disease and chronically 
inflicts 350 million people worldwide [43].   Human Immunodeficiency virus (HIV) attacks the 
human immune system, depriving the body of fighting off infection.  Currently, 33 million 
people are living with this dangerous disease[44] .  These viral infections are very aggressive due 
to the precision of the virus life cycle, especially replication within the host.  
 Due to the potency of these diseases and their widespread effect on human health, many 
drugs have been developed to treat these viral infections.  While there are many kinds of 
treatments used to allay these infections, this study will focus on a particular class of drugs, 
known as nucleoside analogs.  Nucleoside analogs are a class of antiviral drugs that mimic 
natural nucleotides due to their similar structure and inhibit viral replication in infected host 
cells.  These drugs are administered as nucleosides, however, they are phosphorylated by the 
kinases of the host cell [45].  Currently twelve different nucleoside analog drugs have been 
approved by the Food and Drug Adminstration (FDA) for the treatment of HBV and HIV alone.  
Of these twelve drugs, this study will focus on five nucleoside analogs.  A structural 
representation of these drugs can be seen in Figure 3.1.   
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Figure 3.1: Structure of nucleoside analogs used for this study.  Red represents changes to 
the ribose. Green represents modifications to the base.  Blue represents other types of 
modifications 
 Of these drugs, Entecavir (ETV) and Adefovir (PMEA) are used to treat HBV [46], while 
Zidovudine (AZT) and Emtricitabine (L-FTC) are used for treatment of HIV [47].  Tenofovir 
(PMPA) has been approved to treat both HBV and HIV.  These analogs are different from the 
natural nucleotides due to modifications to the ribose sugar, change to the base, or inversion of 
orientation.  One important feature of many of these drugs is that they lack a 3’ hydroxyl group.  
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Thus, if these drugs are incorporated, replication will be terminated.   
 When administered, there is nothing about the structure of these drugs that inhibits their 
incorporation into the human genome by the host DNA polymerases.   If these drugs are 
incorporated into the host genome, they will discontinue replication of the genome, which will 
lead to cell death.  Thus, these drugs may be substrates for the human DNA polymerases and 
incorporation into the human genome of these nucleotide analogs could be the cause of many of 
the side effects associated with these drugs [48].  However, before these nucleoside analogs are 
approved by the FDA, they are tested with the “classical” DNA polymerases to ensure a low 
selectivity of the nucleotide analog over the natural nucleotide.   Thus, many studies have shown 
that the “classical” DNA polymerases have a low probability of incorporating these drugs.   
Conversely, no studies have been done investigating these analogs with the recently discovered 
X- and Y- family DNA Polymerases.  Thus, the aim of this project will be to investigate if these 
nucleoside analogs are substrates for X- and Y-family DNA polymerases. 
 The human X-family DNA polymerases include human DNA polymerase Lambda 
(hPolλ), Beta (hPolβ), mew (hPolµ), and terminal deoxynucleotidyl transferase (TdT).  Despite 
belonging to the same family, these polymerases have quite different in vivo functions.  For 
example, TdT randomly incorporates nucleotides at the ends of DNA during V(D)J 
recombination, while hPolβ is a major participant in Base Excision Repair (BER) [49].   Overall, 
these X-family DNA polymerases tend to play a role in several DNA repair pathways. hPolλ was 
selected as the model X-family DNA polymerase to determine if the aforementioned nucleotide 
analogs would be substrates for this essential family of enzymes.  hPolλ was chosen due to its 
overall sequence homology to the other members of its family.  In addition, the role of hPolλ is 
 55 
for the most part unknown.  However, hPolλ has been suggested to have a role in several DNA 
repair pathways including DNA repair synthesis in meiosis [50], “short patch” BER [51], in the 
proliferating cell nuclear antigen-dependent BER [52], and in the repair of double stranded 
breaks through base excision repair [53].  
 Besides determining if nucleoside analogs are substrates for the repair enzymes of the X-
family, we also analyzed whether these drugs would be incorporated by the Y-family of DNA 
polymerases.  The Y-family DNA polymerases have been mentioned in the previous chapters 
due to their role in translesion synthesis.  As mentioned previously, four Y-family DNA 
polymerases have been identified in humans.  These include human DNA polymerases eta 
(hPolη), iota (hPolι), kappa (hPolκ), and Rev1.  hPolη was chosen as the model Y-family DNA 
polymerase due to its known function in cis-syn thymine-thymine dimer lesion bypass [27].  
Thus, we determined whether five nucleotide analogs would be substrates for model X-and Y-
family DNA polymerases, hPolλ and hPolη, respectively. 
 
Methods 
 Materials- For this project, OptiKinase from United Biochemical (Cleveland, OH), [γ-
32P]ATP from GE Healthcare, and dNTPs from Invitrogen were purchased.  The full length 
hPolλ and hPol η were expressed in E. coli and purified within the Suo laboratory. 
 Synthetic Oligonucleotides- DNA templates and primers (Table 3.1) were purchased from 
Integrated DNA Technologies (Coralville, IA) and purified using denaturing PAGE.  The 
concentration of these DNA oligonucleotides was determined using UV spectroscopy at 260 nm. 
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 Radiolabeling and Annealing DA substrates- The 21-mer primer was 5’-32P-labeled by 
incubating it with Optikinase and [γ-32P]ATP for 3 hours at 37 ˚C.  This radiolabeled primer was 
annealed to an unlabeled template, in which the nucleotide analog would be a “correct” 
incorporation, at a molar ratio of 1.00:1.15.  Due to the fact that hPolλ likely has a role in DNA 
gap filling, templates for hPolλ experiments were also annealed to a downstream primer, 19-mer-
5’P or 19mer2-5’P.  The annealing mixtures were heated to 95 ˚C for five minutes and then 
slowly cooled to room temperature. 
 Buffers:  Pre-steady-state kinetic assays for hPolη were performed in optimized buffer R 
(50 mM HEPES, pH 7.5 at 37 ˚C, 5 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA, 5mM 
dithiothreitol, 10% glycerol, and 0.1 mg/mL bovine serum albumin).  For hPolλ, pre-steady-state 
kinetic assays were performed in buffer L (50mM Tris-Cl(pH 8.4 at 37 °C), 5 mM MgCl2, 100 
mM NaCl, 0.1 mM EDTA, 5 mM DTT, 10% glycerol, 0.1 mg/mL BSA).  The concentrations 
indicated above were those of the final mixed solutions. 
 Determination of Selectivity Factor- Like in Chapter 1, pre-steady state single turnover 
Table 3.1 Sequences of DNA oligonucleotides 
Primers 
21-mer 5′-CGCAGCCGTCCAACCAACTCA-3’ 
19-mer-5’P 5′-PCGTCGATCCAATGCCGTCC-3’ 
19-mer2-5’P 5′-PAGTCGATCCAATGCCGTCC-3’ 
Templates 
41-mer D-8 3’-GCGTCGGCAGGTTGGTTGAGTCGCAGCTAGGTTACGGCAGG-5’ 
41-mer D-6t 3’-GCGTCGGCAGGTTGGTTGAGTGTCAGCTAGGTTACGGCAGG-5’ 
41-mer D-1 3’-GCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5’ 
41-mer D-7 3’-GCGTCGGCAGGTTGGTTGAGTTGCAGCTAGGTTACGGCAGG-5’ 
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dNTP incorporation assays were employed to determine the kp and Kd, dTP, where the kp is the 
maximum rate of incorporation of a dNTP and Kd, dTP is the equilibrium dissociation constant of 
an incoming nucleotide.  In brief, a solution of 5’-32P-labeled DNA (30 nM) and Dpo4 (120 nM) 
in buffer R or L was pre-incubated at 37 ˚C and subsequently mixed with solutions containing 
increasing amounts of a single natural nucleotide or nucleotide analog.  These reactions were 
quenched using the rapid-chemical quench or manually after various time points using 0.37 M 
EDTA.  The formed product was separated from the initial primer by denaturing PAGE (17% 
acrylamide, 8 M urea) and quantitated with a Phosphorimager 445 SI.  For each concentration of 
natural nucleotide or corresponding analog, the function of product formation per time point was 
fit to a single exponential equation (Equation 1.2).  Where kobs is the observed reaction rate 
constant, and A is the reaction’s product formation amplitude.  Next, the values of the kobs were 
plotted against the concentration of dNTP for the respective reaction.  This relationship was fit to 
a hyperbolic equation (Equation 1.3). Where, as stated previously, kp is the maximum rate of 
dNTP incorporation, and the Kd,dTP is the dissociation constant for the ternary complex 
(Dpo4·DNA·dNTP) at equilibrium.  Combining these terms, the substrate specificity was 
determined by taking the ratio of the kp over the Kd,dNTP.  The selectivity factor was determined 
by comparing the substrate specificity of the natural nucleotide over the substrate specificity of 
the nucleotide analog.   Here, a higher selectivity factor would indicate a high probability of 
incorporation of the natural nucleotide over the nucleotide analog drug.  
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Results 
Determining the Selectivity Factors for each ucleotide Analog- As stated earlier, the 
selectivity factor is determined by comparing the ratio of the substrate specificities of the natural 
nucleotide to the nucleotide analog.  The substrate specificity is a term that combines the kp and 
Kd,DA by taking the former over the later (kp/ Kd,DA).  In order to determine the kp and Kd,DA, we 
performed single dNTP incorporation assays under single-turnover reaction conditions.  In this 
assay, a pre-incubated solution of DNA polymerase (either hPolλ or hPolη) (120 nM) and 5’-32P-
labeled DNA substrate are rapidly mixed with either the natural nucleotide or nucleotide analog 
and quenched at various time points with .37M EDTA. The products are then separated using 
PAGE. The product formation is then plotted against time and fit to Equation 1.2 to determine 
the observed reaction rate (kobs) (Figure3.2).    
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Figure 3.2: Relationship of product formation versus time for PMPA and hPolη. Each time 
course was fit to Eq 1.2 to yield a kobs. 
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The dependence of kobs on the concentration of the dNTP is then plotted and fit to 
Equation 1.3, which yields values for the kp and Kd, DA (Figure3.3).  The determined kinetic 
results of the incorporation of both natural nucleotides and nucleotide analogs by hPolλ and 
hPolη are summarized in Table 3.2 and Table 3.3. 
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Figure 3.3: The Plot of Observed Rate Constant against Concentration. The plot of kobs 
values against PMPA concentrations was fit to Eq 1.3.  
Table 3.2: Kinetic Parameters for hPolλ’s incorporation of a natural nucleotide or 
nucleotide analog 
A 
kp 
(s
-1
) 
Kd 
(µM) 
kp/Kd 
(µM
-1
s
-1
) 
Selection 
Factor
a
 
dCTP 1.57 ± 0.04 0.9 ± 0.1 1.7  
L-FTC-TP 0.0049 ± 0.0001 0.36 ± 0.03 0.014 121 
 
dATP 1.5 ± 0.1 0.9 ± 0.3 1.7  
PMPA-DP 0.095 ± 0.008 3.7 ± 0.9 0.026 65 
PMEA-DP 0.175 ± 0.004 4.5 ± 0.3 0.039 44 
 
dGTP 2.5 ± 0.1 2.1 ± 0.3 1.2  
ETV-TP 0.034 ± 0.002 0.09 ± 0.02 0.38 3.2 
 
dTTP 3.9 ± 0.2 2.6 ± 0.4 1.5  
AZT-TP 1.83 ± 0.09 12 ± 2 0.15 10 
aCalculated as (kp/Kd)dNTP/(kp/Kd)NA. 
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Table 3.3: Kinetic Parameters for hPolη’s incorporation of a natural nucleotide or 
nucleotide analog 
A 
kp 
(s
-1
) 
Kd 
(µM) 
kp/Kd 
(µM
-1
s
-1
) 
Selection 
Factor
a
 
dCTP 49 ± 2 25 ± 4 1.96  
L-FTC-TP 0.0244 ± 0.0004 2.7 ± 0.1 9.0 x 10-3 217 
 
dATP 35 ± 3 130 ± 26 0.27  
PMPA-DP 0.0134 ± 0.007 90 ± 10 1.5 x 10-4 1,800 
PMEA-DP 0.069 ± 0.008 55 ± 18 1.3 x 10-3 208 
 
dGTP 38 ± 2 80 ± 12 0.48  
ETV-TP 0.24 ± 0.01 2.4 ± 0.4 0.1 5 
 
dTTP 35 ± 1 41 ± 5 0.85  
AZT-TP 0.31 ± 0.05 478 ± 155 6.5 x 10-4 1,300 
 
aCalculated as (kp/Kd)dNTP/(kp/Kd)NA. 
 
By dividing the kp by the Kd, DA, these terms were combined to determine the substrate 
specificity.  To analyze the potential of each nucleotide analog to be incorporated by either DNA 
polymerase, the substrate specificity of the natural nucleotide was compared to that of the 
nucleotide analog.  Thus, the selectivity factor was determined by taking the ratio of the substrate 
specificity of the natural nucleotide over substrate specificity of the nucleotide analog.   
The pre-steady state kinetic analysis of hPolλ and hPolη’s incorporation of the various 
nucleotide analogs indicated that these drugs could be incorporated into the human genome.  
Interstingly, the hPolλ and hPolη had different order of preferences for the studied group of 
nucleotide analogs.  hPolλ’s substrate preference was L-FTC-TP< PMPA-DP < PMEA-
DP<AZT-TP< ETV-TP.  The substrate preference of hPolη was PMPA-DP<AZT-TP<L-FTC-
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TP<PMEA-DP<ETV-TP.  Thus, while both hPolλ and hPolη are capable of incorporating these 
nucleotide analogs, they do so with different specificities.   
 
Discussion 
 Nucleoside analog drugs play a significant role in the treatment of viral infections, 
especially HBV and HIV.  They function to inhibit the viral replication machinery and reduce the 
rate of replication of the virus within the host.  These drugs, however, may also interfere with the 
human host’s DNA replication.  While some research has been done studying the “classical” 
DNA polymerases ability to select the natural nucleotide over the analog, currently, no studies 
have been performed to determine the selectivity of other families of polymerases.  Thus, this 
project investigated the selectivity of incorporation for polymerases that model the X- and Y-
family DNA polymerases, hPolλ and hPolη, respectively.  
 Through the utilization of pre-steady state kinetic assays, we were able to determine the 
microscopic kinetic parameters for the incorporation of each nucleotide analog and 
corresponding natural nucleotide by either hPolλ or hPolη.  We compared the substrate 
specificites for each nucleotide analog with the corresponding natural nucleotide to determine the 
selectivity of the polymerase for the natural nucleotide over the analog.  Thus, we used these 
selectivity factors to demonstrate the likelihood of each nucleotide analog to be incorporated by 
the polymerase.   
A high selectivity factor is associated with a low probability of incorporation of the 
nucleotide analog.  When a drug is being developed, the company tries to identify analogs with a 
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low selectivity for the viral replication machinery but a high selectivity for the human DNA 
polymerases. In addition, the pharmaceutical companies follow a standard that the selectivity 
factor for incorporation of the analog by the “classical” replicative polymerases must be greater 
than 500, indicating that the drug is a poor substrate for these enzymes.  Comparing this standard 
to the results in Tables 3.2 and 3.3, it is obvious that many of these drugs would not meet the 
standard if it was broadened to the DNA polymerases responsible for translesion synthesis and 
DNA repair.  All the nucleoside analog drugs that were tested with hPolλ had a selectivity factor 
less than the standard (Figure 3.4).  
 
Figure 3.4: Selectivity factors for hPolλ 
Thus, all these drugs may be substrates for the X-family DNA polymerases in vivo.  hPolη had 
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selectivity factors lower than the standard for ETV, PMEA, and L-FTC.  Based on these results, 
these drugs would likely be substrates for Y-family DNA polymerases.  Contrastingly, the 
selectivity factors for hPolη’s incorporation of PMPA and AZT were well above the 500 
standard.  Thus, these drugs would be unlikely to be incorporated by the Y-family.  A 
comparison of the selectivity factors for the aforementioned nucleotide analogs is shown in 
Figure 3.5.  
 
Figure 3.5: Selectivity factors for hPolη 
Interestingly, the selectivity factors for ETV’s incorporation by hPolλ and hPolη were the 
lowest of all the other drugs tested for both enzymes.  Moreover, the selectivity factors for ETV 
incorporation were less than 10.  This data indicates that the incorporation of ETV into the 
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human genome by both X- and Y-family DNA polymerases is almost as probable as 
incorporation of a natural nucleotide.  The reason for these low selectivity factor seems to arise 
from the tight binding of ETV to the ternary complex rather than an increased rate of 
incorporation.   
The low selectivity factors of incorporation of ETV as well as many of the other 
nucleotide analogs by hPolλ and hPolη indicate that these drugs could be incorporated into the 
human genome.  These polymerases seem unable to distinguish the analogs from their 
corresponding natural nucleotides.  If the X- and Y- family DNA polymerases are employed and 
a patient is being treated with one of the aforementioned nucleoside analogs, these enzymes will 
likely incorporate the analog and thus terminate replication of the human genome.  The results 
presented could provide insight into the toxicity and side effects associated with treatment 
consisting of nucleoside analog drugs.  More specifically, he observed clinical toxicity may be 
related to the potential incorporation of these nucleotide analogs catalyzed by human X- and Y-
family DNA polymerases in vivo. 
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Conclusion 
 In Chapter 1, the bypass mechanism of a single base lesion, dGAP, was determined for a 
model Y-family DNA polymerase, Dpo4.  We found that while Dpo4 is capable of bypassing the 
dGAP lesion, its rate is significantly perturbed when encountering the lesion.  Moreover, the 
polymerase stalls in its incorporation directly across from lesion and in the extension of the 
bypass product one nucleotide downstream.  This stalling was largely due to the decrease in 
correct dNTP incorporation efficiencies at the pause sites.  Finally, we learned that the bypass of 
the dGAP lesion demonstrated biphasic kinetics.  From this finding, we hypothesized that the 
some of the ternary complexes were bound in an unproductive conformation and thus required 
transformation to a more productive complex.   
 In Chapter 2, the mutagenic profiles for the bypass of the dGAP lesion by Dpo4, h∆Polκ, 
and hPolη were determined using a novel assay, known as SOSA.  We utilized this assay to 
sequence the bypass products of the replication opposite a template containing dGAP.  The 
sequencing results from this chapter showed the individual substitutions, additions, and deletions 
that occurred in bypass of the dGAP lesion.  Our study showed that Dpo4 sequenced a correct 
dCTP opposite the lesion in 90% of the sequence spectra.  Contrastingly, h∆Polκ, and hPolη 
indiscriminately synthesized the bypass product opposite the lesion.  When comparing, these two 
human Y-family DNA polymerases, it seems that although hPolη bypasses the lesion with more 
kinetic efficiency, h∆Polκ maintains a greater fidelity.   
 Finally, in Chapter 3, we analyzed the potential of nucleoside analog drugs to be 
 66 
incorporated by X- and Y-family DNA polymerases, which were modeled by hPolλ and hPolη, 
respectively.  Nucleoside analogs are meant to disrupt the replication machinery of the virus to 
slow its growth within the host.  These analogs may become substrates for the human DNA 
polymerases, causing the replication of the human genome to be terminated.  The microscopic 
kinetic parameters for the incorporation of both nucleotide analogs and their corresponding 
natural nucleotide were determined using pre-steady state kinetic assays.  These parameters were 
compared to determine the selectivity factor for each nucleoside analog.  The results showed that 
many of the analogs studied had low selectivity, indicating that they would likely be 
incorporated by either the X- or Y-family DNA polymerases.  The demonstrated potential of 
these nucleoside analogs to be incorporated into the human genome by X- and Y-family DNA 
polymerases may relate to the observed clinical toxicity of many of these drugs.  
 Overall, this thesis outlines my progression as a researcher in the Suo laboratory.  It 
provides detailed explanations of a few of my projects in the lab that have mainly been in 
collaboration with Jessica Brown and Shanen Sherrer. Besides, contributing to my growth as a 
researcher, these projects have contributed to general scientific understanding of X- and Y- 
family DNA polymerases.  
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Appendix 1 
 
Supplementary Table 1. Kinetic parameters of dNTP incorporation into undamaged DNA (26-mer) 
 
Kd, dTP 
(µM) 
kp 
(s
-1
) 
kp/Kd, dTP 
(µM
-1
s
-1
)
 Fidelity
a
 
19/26-mer 
dGTP             183 ± 54 4.6 ± 0.4 2.5 x 10-2 - 
dATP 731 ± 175 (1.0 ± 0.1) x 10-2 1.4 x 10-5 5.6 x 10-4 
dCTP 350 ± 107 (5.0 ± 0.5) x 10-2 1.4 x 10-4 5.6 x 10-3 
dTTP           1440 ± 305 (1.3 ± 0.2) x 10-2 8.9 x 10-6 3.6 x 10-4 
20/26-mer 
dCTP             205 ± 64 11.6 ± 0.9 5.7 x 10-2 - 
dATP 631 ± 136 (1.2 ± 0.1) x 10-2 1.9 x 10-5 3.3 x 10-4 
dGTP 77 ± 16 (3.5 ± 0.2) x 10-3 4.5 x 10-5 7.9 x 10-4 
dTTP             489 ± 52 (4.0 ± 0.2) x 10-2 8.3 x 10-5 1.5 x 10-3 
21/26-mer 
dGTP             437 ± 19 1.62 ± 0.03 3.7 x 10-3 - 
dATP 859 ± 168 (2.0 ± 0.2) x 10-3 2.4 x 10-6 6.5 x 10-4 
dCTP             701 ± 30 (2.14 ± 0.04) x 10-2 3.1 x 10-5 8.3 x 10-3 
dTTP           1180 ± 144 (2.1 ± 0.2) x 10-3 1.8 x 10-6 4.9 x 10-4 
22/26-mer 
dCTP             129 ± 19 4.4 ± 0.2 3.4 x 10-2 - 
dATP           1313 ± 154 (5.5 ± 0.4) x 10-3 4.2 x 10-6 1.2 x 10-4 
dGTP             567 ± 95 (4.8  ± 0.4)  x 10-3 8.5 x 10-6 2.5 x 10-4 
dTTP           1340 ± 454  (1.5  ± 0.3)  x 10-2 1.1 x 10-5 3.2 x 10-4 
23/26-mer 
dGTP             116 ± 24 2.8 ± 0.1 2.4 x 10-2 - 
dATP             431 ± 25 (6.6 ± 0.1) x 10-3 1.5 x 10-5 6.2 x 10-4 
dCTP             918 ± 102 (1.5 ± 0.1) x 10-3 1.6 x 10-6 6.7 x 10-5 
dTTP           1220 ± 59 (3.8 ± 0.1) x 10-3 3.1 x 10-6 1.3 x 10-4 
aCalculated as (kp/Kd, dNTP)incorrect/[(kp/Kd, dNTP)correct + (kp/Kd, dNTP)incorrect]. 
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Figure A2.1:  Mutations at each position for Dpo4’s replication of 17/73-mer. 
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Figure A2.2:  Mutations at each position for Dpo4’s replication of 17/73-mer-dG
AP
. 
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Figure A2.3:  Mutations at each position for hIPolκ’s replication of 17/73-mer-dG
AP
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Figure A2.4:  Mutations at each position for hPolη’s replication of 17/73-mer-dG
AP
. 
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